Phase I Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years
Phase of Trial: Phase I
Latest Information Update: 05 Nov 2014
At a glance
- Drugs VAX 161 (Primary)
- Indications Influenza A virus H5N1 subtype
- Focus Adverse reactions
- 01 Nov 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 12 Jun 2012 Planned number of patients changed from 200 to 250.